Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031577 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1029374 | 0.90 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3807999 | 0.90 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1029510 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1029509 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1028355 | 0.80 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1028354 | 0.80 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1029668 | 0.80 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1028337 | 0.78 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1028811 | 0.78 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957493-B1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | ORGANON NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| EP-1957493-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-08-20 | — | — | EP | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | SLC6A4 903/4885SLC6A2 511/4885SLC6A3 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.